



Letter to the Editor

Patients with very severe anemia: a case series



Dear Editor,

Anemia occurs commonly worldwide and at all ages of life¹ and, although frequently overlooked, it affects mortality, morbidity and quality of life, even when mild.^{2,3} The prevalence of anemia varies widely depending on its definition. The World Health Organization has established some cut-off hemoglobin (Hb) levels, stratified by gender and in part by age, to define the presence of anemia.⁴ For adults, these levels are less than 12 g/dL for women and less than 13 g/dL for men, although these cut-off points may not be fully appropriate for the elderly.⁵ Severe anemia has been defined as Hb <8.0 g/dL for both genders. However, hemoglobin is a simple surrogate marker for the disease that has provoked anemia. To treat anemias simply restoring a “safer” hemoglobin level (i.e., by means of transfusions or erythropoietin) may be very different than curing them by eliminating the causes that had provoked the condition. Moreover, several reports have shown that both transfusions and erythropoiesis stimulating agents may indeed carry an increased risk of adverse events. Therefore, it is quite surprisingly that in health services, anemia continues to be regarded as a “minor” disease, even when severe, to be assigned to the ambulatory setting in the absence of a robust body of literature to support this common practice.

In Italy, disorders of red blood cells in people older than 17 years [International Classification of Diseases – ninth revision Clinical Modification (ICD-IX-CM) codes 280–285] “outside urgencies” are considered not to be appropriate for hospital admission, regardless of the severity of the Hb deficiency or the presence of important comorbidities, including a reduced functional capacity in older people.⁶ We believe that to rely on assumptions of this kind in advance of evidence may carry a risk to induce some potentially deleterious consequences, including overuse of blood transfusions to reach an Hb level “safe” for emergency room discharge rather than patient clinical status. Historically, and in current guidelines,⁷ the indication for transfusion comes from both Hb concentration and the clinical scenario; to transfuse in order to avoid hospital admission should be regarded as unethical.

We conducted an observational, prospective study of all patients admitted to an Internal Medicine ward with very severe anemia, aiming to explore the clinical and assistential burden of severely anemic patients admitted to the hospital. Patients with an Hb concentration of 6 g/dL or less were

Table 1 – Hierarchy of the procedures for International Classification of Diseases (ninth revision) Clinical Modification coding.

1. Open surgery
2. Endoscopic surgical procedures
3. Other invasive diagnostic or therapeutic procedures
4. Procedures with closed biopsy of organ or tissues
5. All other diagnostic or therapeutic procedures

eligible. Those presenting with overt hemorrhage or acute anemia were excluded. Patients were managed as usual, and no diagnostic or therapeutic procedure was performed for study purposes alone. In defining the main diagnosis at discharge, our standard procedure was to select first the procedure that had absorbed the largest amount of resources, accordingly to a predefined hierarchy (Table 1) and then to choose the consequent diagnosis. Accordingly to our laboratory, we defined microcytic anemia as all cases with a mean corpuscular volume (MCV) of less than 81 fL, and macrocytic anemia as those with a MCV of more than 98 fL and normocytic anemia as all others. Thrombocytopenia was defined as an absolute platelet count of less than $150 \times 10^9/L$; leukopenia as a white blood cell absolute count of less than $4.0 \times 10^9/L$ and lymphopenia as an absolute lymphocyte count of less than $1.1 \times 10^9/L$.

The main outcome of the study was all-cause, in-hospital mortality. Secondary outcomes were one-year mortality and the percentage of admissions for anemia that were lost to a retrospective analysis based only on coding. Continuous variables are expressed as means \pm standard deviation (SD) or as medians with minimum and maximum values when data did not have a normal distribution; categorical data are given as counts and percentages. The Institutional Review Board approved the study, which was carried out and is reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for observational studies.⁸

Between October 2009 and June 2015, 86 patients were admitted for very severe anemia. Of these, 61 (71%) were women and 25 (29%) were men; eight patients (9.3%) came from nursing homes, one from a prison and the remaining cases were from home. The mean age was 76.8 ± 15.6 (range: 33–100). Seventy-one patients (82.5%) were 65 years or older. Nine of the patients (six women and three men) died during

Table 2 – Hematological data.

	Discharged 77 (89.5%)	Deceased 9 (10.5%)	p-Value
Mean Hb, g/dL – n (SD)	5.02 (0.81)	5.43 (0.71)	ns
Mean MCV, fL – n (SD)	85.4 (20.7)	88.4 (16.6)	ns
Microcytic – n (%)	42 (54.5)	2 (22.2)	ns ^a
Normocytic – n (%)	14 (18.2)	5 (55.6)	<0.05 ^b
Macrocytic – n (%)	21 (27.3)	2 (22.2)	ns ^c
Thrombocytopenia – n (%)	14 (18.2)	2 (22.2)	ns
Leukopenia – n (%)	12 (15.6)	1 (11.1)	ns
Lymphopenia – n (%)	25 (32.5)	4 (44.4)	ns

^a As compared with non-microcytic anemias.
^b As compared with microcytic anemias.
^c As compared with non-macrocytic anemias.

hospitalization (10.5%); the remaining 77 patients were discharged and followed up for about 170 patient-years. Deceased patients were older than discharged patients: mean age was 90 ± 10 vs. 75.5 ± 15.7 (p -value <0.01). During the same period, general in-hospital mortality was 12.3%. Mean follow-up was 806 days (range: 16–2072 days) during which time 32 more patients died. Mean time to death was 412 days. The cumulative percentages of death at 1, 3 and 12 months were 3.9%, 13.0% and 29.9%, respectively. When in-hospital mortality was

included and added to one-month mortality, the corresponding figures became 13.9%, 22.1% and 37.2%. Hematological data are shown in Table 2. There were no significant differences in mean Hb and MCV, or in the presence of cytopenias other than anemia. However, discharged patients more often had microcytic anemias (54.5%) compared to deceased patients, whose anemias were more often normocytic or macrocytic (77.8%). Patients with a normocytic anemia had an increased risk to die in the hospital when compared with those with microcytic

Table 3 – Diagnosis Related Groups (DRG) accordingly to International Classification of Diseases (ninth revision) Clinical Modification coding.

DRG	Type	Number of cases
12 - Degenerative nervous system disorders	MED	1
14 - Intracranial hemorrhage or cerebral infarction	MED	1
122 - Circulatory disorders W AMI W/O major comp, discharged alive	MED	1
123 - Circulatory disorders W AMI, expired	MED	1
135 - Cardiac congenital & valvular disorders age >17W CC	MED	1
138 - Cardiac arrhythmia & conduction disorders W CC	MED	1
142 - Syncope & collapse W/O CC	MED	1
144 - Other circulatory system diagnoses W CC	MED	1
172 - Digestive malignancy W CC	MED	6
174 - Gastrointestinal hemorrhage W CC	MED	8
179 - Inflammatory bowel disease	MED	1
180 - Gastrointestinal obstruction W CC	MED	1
182 - Esophagitis, gastroent & misc digest disorders age >17W CC	MED	4
188 - Other digestive system diagnoses AGE >17W CC	MED	1
189 - Other digestive system diagnoses age >17 W/O CC	MED	1
190 - Other digestive system diagnoses age 0–17	MED	1
239 - Pathological fractures & musculoskeletal & conn tiss malignancy	MED	1
271 - Skin ulcers	MED	1
304 - Kidney, ureter & major bladder proc for non-neopl W CC	SURG	1
310 - Transurethral procedures W CC	SURG	1
316 - Renal failure	MED	2
395 - Red blood cell disorders age >17	MED	31
• Iron deficiency anemia		19
• Secondary or not specified anemia		6
• Myelodysplasia		2
• Pancytopenia		2
• Megaloblastic anemia		2
397 - Coagulation disorders	MED	2
403 - Lymphoma & non-acute leukemia W CC	MED	2
473 - Acute leukemia W/O major O.R. procedure age >17	MED	1
570 - Major small & large bowel procedures W CC W/O major GI DX	SURG	1
571 - Major esophageal disorders	MED	1
574 - Major hematologic/immunologic dx excep sickle cell crisis & coag	MED	6
576 - Septicemia w mechanical ventilator w/0 96+ hours age >17	MED	4
All		85

anemia (OR 7.5; 95% confidence interval: 1.3–43.1; p -value <0.05). Lymphopenia, a surrogate marker for hyponutrition, was more prevalent in deceased patients (44.4% vs. 32.5%).

A total of 295 units of packed red cells were transfused to the 77 discharged patients (mean: 3.8), and 29 units to the nine deceased patients (mean: 3.2). One patient who died refused blood transfusions because of religious beliefs. Patients discharged alive were submitted to 77 invasive procedures: 39 to esophagogastroduodenoscopy, 23 to colonoscopy, four to capsular videoendoscopy (preceded by radiologic study of gastrointestinal tract in all four cases) and 11 to bone marrow biopsies. Administrative data was complete for 85 cases (98.8%). Diagnosis Related Groups (DRG) according to the ICD-IX-CM coding are shown in [Table 3](#); three were surgical, and the remaining were clinical. Only 31/85 cases were coded as DRG 395 (red blood cell disorders – age >17), so about 63% of patients admitted for anemia would have been lost if this survey had been conducted retrospectively on discharge data. The mean reimbursement was 3165 euros.

In this preliminary study, we report data on a sample of 86 consecutive, unselected elderly patients (82.5% of whom were 65 years or older). In-hospital mortality was 10.5%, but more than one third of these patients eventually died within a year after the index admission. Discharged patients, as compared with those who died in the hospital, had microcytic anemias more often (54.5% vs. 22.2%). Conversely, deceased patients had a high prevalence of normocytic anemias (18.2% vs. 55.6%). We speculate that microcytic anemia could have been more often the expression of a single and possibly curable disease, whereas normocytic anemias should be the result of multiple comorbidities that played the main role in causing death. In our study, we demonstrated that very severe anemia is not a benign condition with high mortality, and we question the advisability of hospitalization. In many cases anemia could be managed without transfusions (i.e., iron and vitamin B12 deficiency, chronic renal insufficiency, myelodysplasia and chemotherapy-related anemia), but this is often impossible without patient monitoring, and there is a risk of overuse of blood transfusions in this kind of patient in order to discharge them from the Emergency Department. To clarify this issue there is a need for prospective, randomized studies; indeed in our cohort, 63% of discharge diagnoses were not in the DRG 395 group, and would have been missed if we conducted an investigation based on administrative data only. We acknowledge some limitations of this study beyond its observational nature. This is a single-center experience, and results may not be reproducible in other contexts. However, we recruited all consecutive patients with very severe anemia over a period of more than five years, and we excluded only patients with acute anemia from bleeding. Furthermore, with about 170 patient-years of observation, we think that data on mortality are sufficiently robust. We enrolled patients on the basis of an arbitrary threshold of Hb that we defined as “very severe”. Indeed, 33 patients had Hb less than 5.0 g/dL, and 13 less than 4 g/dL, values that should be regarded as life threatening, especially in old, comorbid patients. There is little doubt that if we chose a more permissive approach (i.e., an Hb level of 7.0–8.0 g/dL), we would have recruited a wider sample of patients. To study patients with less severe anemia however, was not in our interest, since we focused

on the prognosis of patients for whom there are scarce data in the literature. Our patients were transfused with three to four units of packed red cells each. Due to the observational design of the study, we were not able to elucidate if there was a detrimental effect of transfusions on patient outcomes. Finally, we did not evaluate the impact of comorbidities on mortality in this cohort of patients, but we are planning a follow-up study to address this important question.

Conflicts of interest

The authors declare no conflicts of interest.

REFERENCES

1. Dallman PR, Yip R, Johnson C. Prevalence and causes of anemia in the United States, 1976 to 1980. *Am J Clin Nutr*. 1984;39(3):437–45.
2. Riva E, Tettamanti M, Mosconi P, Apolone G, Gandini F, Nobili A, et al. association of mild anemia with hospitalization and mortality in the elderly: the health and anemia population-based study. *Haematologica*. 2009;94(1):22–8.
3. Nissenson AR, Goodnough LT, Dubois RW. Anemia: not just an innocent bystander? *Arch Intern Med*. 2003;163(12):1400–4.
4. WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. WHO/NMH/NHD/MNM/11.1. [Internet]. Available from: 2011http://apps.who.int/iris/bitstream/10665/85839/3/WHO_NMH.NHD.MNM.11.1.eng.pdf?ua=1.
5. Spivak JL. Anemia in the elderly. Time for new blood in old vessels? *Arch Intern Med*. 2005;165(19):2187–9.
6. Ministero della Salute. Decreto del presidente del consiglio dei ministri 29 novembre 2001. Definizione dei livelli essenziali di assistenza. (G.U. Serie Generale, n. 33 del 08 febbraio 2002).
7. Chronic anaemia. Blood transfusion guideline. Utrecht (The Netherlands): Dutch Institute for Healthcare Improvement CBO; 2011. p. 108–65.
8. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Prev Med*. 2007;45(4):247–51.

Marco Cei^a, Alessandro Ferretti^b, Nicola Mumoli^{b,*}

^a Ospedale Civile di Cecina, Cecina, Italy

^b Ospedale Civile di Livorno, Livorno, Italy

*Corresponding author at: Department of Internal Medicine, Ospedale Civile di Livorno, viale Alfieri 36, 57100 Livorno, Italy. E-mail address: nimumoli@toscali.it (N. Mumoli).

Received 21 January 2017

Accepted 12 February 2017

1516-8484/

© 2017 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<http://dx.doi.org/10.1016/j.bjhh.2017.02.001>

Available online 7 March 2017